Pycnogenol is a standardized extract of the bark of the French maritime pine (Pinus pinaster ssp. atlantica), composed mainly of procyanidins (polymers of catechin and epicatechin) together with phenolic acids and flavonoids such as taxifolin. It is marketed as a dietary supplement and has been characterized as having antioxidant, anti-inflammatory, and antiplatelet properties. Mechanistically, its polyphenols increase the activity and expression of endothelial nitric oxide synthase (eNOS), raising nitric oxide (NO) availability and promoting endothelium-dependent vasodilation, and it also scavenges free radicals and can inhibit angiotensin-converting enzyme.
In human trials, Pycnogenol has improved flow-mediated dilation and other measures of endothelial function in people with coronary artery disease and hypertension, and a meta-analysis of 12 trials reports modest reductions in blood pressure (about 3 mmHg systolic and 2 diastolic), though the effects are often small and inconsistent, and at least one meta-analysis found no significant blood-pressure effect at all. Additional randomized studies suggest possible benefits for blood glucose control, cognitive function, and knee osteoarthritis symptoms, but a Cochrane review graded nearly all outcomes across conditions as very low-certainty evidence — the trials are small, few per condition, and poorly reported — and much of the positive literature originates from one manufacturer-funded research group. Overall the evidence points to plausible cardiovascular and metabolic benefits but remains limited by small sample sizes and frequent industry involvement. This research describes the pine bark extract compound and its mechanisms in general, not this specific commercial product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“Pycnogenol augments endothelium-dependent vasodilation by increasing nitric oxide production”
“The intake of Pycnogenol decreased endothelin-1 concentrations significantly compared to placebo”
“In the randomized SVOS study, Pycnogenol reduced osteoarthritis symptoms and cut anti-inflammatory drug use by 58% versus 1% with placebo.”
“Across three clinical studies, pine bark extract (Pycnogenol) relieved pain, improved stiffness and mobility, and spared NSAID use in osteoarthritis patients.”
“No supplements were identified with clinically important effects on pain reduction at long term.”
“In CAD patients, Pycnogenol treatment was associated with an improvement of FMD from 5.3 ± 2.6 to 7.0 ± 3.1 (P < 0.0001), while no change was observed with placebo (5.4 ± 2.4 to 4.7 ± 2.0; P = 0.051).”
Research describes the active mechanism and is not a claim about this specific product.
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Across meta-analyses and randomized trials, creatine monohydrate combined with…
In humans, randomized trials and meta-analyses most consistently show that astaxanthin…
Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…
Yes — its active compound is linked to 25 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.